BRAF and neoplasm: However, G-5555 partially re-sensitized Rac1-driven BRAFi-resistant tumor cells to BRAF inhibition, both for Vav1 over-expressing cells and for cells expressing the clinically relevant Rac1 P29S constitutively active mutant (Fig. 2A, B).